Needham Maintains Buy on Revance Therapeutics, Raises Price Target to $40
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $38 to $40.
Piper Sandler Maintains Overweight on Revance Therapeutics, Raises Price Target to $40
Piper Sandler analyst David Amsellem maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and raises the price target from $29 to $40.
Morgan Stanley Maintains Equal-Weight on Revance Therapeutics, Raises Price Target to $26
Morgan Stanley analyst Terence Flynn maintains Revance Therapeutics (NASDAQ:RVNC) with a Equal-Weight and raises the price target from $25 to $26.
Here’s Why This Analyst Seems Highly Convinced With Evolus’ Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Needham Maintains Buy on Revance Therapeutics, Raises Price Target to $38
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $35 to $38.
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors’ Attention Today
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500 ended in the red.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
Macy’s, Acuity Brands And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Reported Late Friday, Revance Announces U.S. FDA Acceptance Of Supplemental Biologics License Application For DAXXIFY For Injection For The Treatment Of Cervical Dystonia
- Prescription Drug User Fee Act (PDUFA) date of August 19, 2023 -